Related Experiment Videos
Novel and classical protein kinase C isoforms have different functions in proliferation, survival and differentiation
R Zeidman1, L Pettersson, P R Sailaja
1Lund University, Department of Laboratory Medicine, Molecular Medicine, Malmö University Hospital, Sweden.
Abstract:
To elucidate the possibility of utilizing protein kinase C (PKC) isoforms as target genes in neuroblastoma therapy, 5 neuroblastoma cell lines and neuroblastoma tumor specimens were examined for PKC isoform expression pattern and the cell lines were analyzed for sensitivity to PKC inhibition. All cell lines [IMR-32, LAN-2, LAN-5, SH-SY5Y and SK-N-BE(2)] expressed alpha, betaII, delta and epsilon isoforms of PKC, while no PKCeta or theta protein was detected in any cell line. PKCgamma was found only in LAN-2 cells. PKCalpha, betaII and delta were detected in 5 neuroblastoma tumors and PKCepsilon in 4 out of 5 tumors. Exposure to the PKC inhibitors GF109203X, Gö 6976 or Gö 6983 caused a decrease whereas activation of PKC with 12-O-tetradecanoyl phorbol 13-acetate caused an increase in the number of neuroblastoma cells. The effect of Gö 6976 was due to both inhibited proliferation and to increased apoptosis. While GF109203X suppressed neurite outgrowth induced by a growth factor combination, Gö 6976 potentiated neurite outgrowth. Our data suggest a role for classical PKC isoforms in neuroblastoma growth and survival and for novel isoforms in neurite outgrowth.
Insights
Protein kinase C (PKC) isoforms are expressed in neuroblastoma cells and tumors. Inhibiting classical PKC isoforms reduced neuroblastoma cell growth and increased apoptosis, suggesting therapeutic potential.
Area of Science:
- Oncology
- Molecular Biology
- Neuroscience
Background:
- Neuroblastoma is a pediatric cancer with varied outcomes.
- Protein kinase C (PKC) signaling pathways are implicated in cell growth and differentiation.
- Targeting specific PKC isoforms may offer novel therapeutic strategies for neuroblastoma.
Purpose of the Study:
- To investigate the expression of PKC isoforms in neuroblastoma.
- To evaluate the sensitivity of neuroblastoma cell lines to PKC inhibition.
- To determine the role of PKC isoforms in neuroblastoma cell behavior.
Main Methods:
- Analysis of PKC isoform expression in five neuroblastoma cell lines and tumor specimens.
- Treatment of cell lines with PKC inhibitors (GF109203X, Gö 6976, Gö 6983) and an activator (12-O-tetradecanoyl phorbol 13-acetate).
- Assessment of cell proliferation, apoptosis, and neurite outgrowth.
Main Results:
- All tested neuroblastoma cell lines expressed PKC alpha, betaII, delta, and epsilon isoforms.
- PKC alpha, betaII, and delta were detected in most neuroblastoma tumors.
- PKC inhibition decreased cell number, suppressed proliferation, and induced apoptosis, while activation increased cell number.
- Specific inhibitors differentially affected neurite outgrowth, suggesting distinct roles for PKC isoforms.
Conclusions:
- Classical PKC isoforms play a significant role in neuroblastoma growth and survival.
- Novel PKC isoforms may be involved in regulating neurite outgrowth.
- PKC isoforms represent potential therapeutic targets for neuroblastoma treatment.